SCHEMBL20293286

SCHEMBL20293286

CCOC(=O)Cc1nc2ccc(N3CCCN(C)CC3)cc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.53
BRD4 O60885 7/20 0.50
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
BLM P54132 2/20 0.49
KMT2A Q03164 2/20 0.49
SLCO2B1 O94956 1/20 0.49
GLA P06280 1/20 0.49
RECQL P46063 1/20 0.49
BCL2L1 Q07817 1/20 0.49
SLCO1B3 Q9NPD5 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
SLCO1B1 Q9Y6L6 1/20 0.49
SIRT2 Q8IXJ6 2/20 0.48
SIRT1 Q96EB6 2/20 0.48
PDGFRB P09619 1/20 0.47
FGFR1 P11362 1/20 0.47
KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL985935 0.96 HSD17B10 (0.57) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL3383472 0.91 HSD17B10 (0.58) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL3741042 0.88 HSD17B10 (0.57) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL25780156 0.87 HSD17B10 (0.56) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL3378290 0.85 AKT1 (0.62) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL25780858 0.85 HSD17B10 (0.54) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL25780664 0.85 HSD17B10 (0.56) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL25780308 0.84 HSD17B10 (0.51) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL25780050 0.84 HSD17B10 (0.53) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1
SCHEMBL25781087 0.83 HSD17B10 (0.54) HSD17B10BRD4ALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113214287-B HPK1 inhibitors and methods of use thereof 大学健康网络 2023-10-20 CN disclosed
WO-2023109902-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF IN MEDICINE 海思科医药集团股份有限公司 2023-06-22 WO disclosed
US-20220002313-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2022-01-06 US disclosed
US-20220002313-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2022-01-06 US disclosed
CN-113214287-A HPK1 inhibitors and methods of use thereof 大学健康网络 2021-08-06 CN disclosed
US-11059832-B2 HPK1 inhibitors and methods of using same UNIVERSITY HEALTH NETWORK (CA) 2021-07-13 US disclosed
US-11059832-B2 HPK1 inhibitors and methods of using same UNIVERSITY HEALTH NETWORK (CA) 2021-07-13 US disclosed
CN-107922431-B HPK1 inhibitors and methods of use thereof 大学健康网络 2021-06-04 CN disclosed
EP-3322711-B1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIV HEALTH NETWORK (CA) 2021-03-10 EP disclosed
EP-3322711-B1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIV HEALTH NETWORK (CA) 2021-03-10 EP disclosed
US-20200190104-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2020-06-18 US disclosed
US-20200190104-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2020-06-18 US disclosed
US-20180179221-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2018-06-28 US disclosed
US-20180179221-A1 HPK1 INHIBITORS AND METHODS OF USING SAME UNIVERSITY HEALTH NETWORK (CA) 2018-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11059832-B2 HPK1 inhibitors and methods of using same PDXK, PDK3, PDK2 HSD17B10 1233/4885BRD4 1780/4885ALDH1A1 2442/4885
US-20180179221-A1 HPK1 INHIBITORS AND METHODS OF USING SAME PDXK, PDK3, PDK2 HSD17B10 1233/4885BRD4 1780/4885ALDH1A1 2442/4885
US-20220002313-A1 HPK1 INHIBITORS AND METHODS OF USING SAME PDXK, PDK3, PDK2 HSD17B10 1201/4885BRD4 1938/4885ALDH1A1 2458/4885
US-20200190104-A1 HPK1 INHIBITORS AND METHODS OF USING SAME PDXK, PDK3, PDK2 HSD17B10 1233/4885BRD4 1780/4885ALDH1A1 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.